Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Top Cited Papers
Open Access
- 8 January 2020
- Vol. 69 (6), 1019-1026
- https://doi.org/10.1136/gutjnl-2019-319954
Abstract
Objective To date, no randomised trials have compared the efficacy of vonoprazan and amoxicillin dual therapy with other standard regimens for Helicobacter pylori treatment. This study aimed to investigate the efficacy of the 7-day vonoprazan and low-dose amoxicillin dual therapy as a first-line H. pylori treatment, and compared this with vonoprazan-based triple therapy. Design This prospective, randomised clinical trial was performed at seven Japanese institutions. Patients with H. pylori–positive culture test and naive to treatment were randomly assigned in a 1:1 ratio to either VA-dual therapy (vonoprazan 20 mg+amoxicillin 750 mg twice/day) or VAC-triple therapy (vonoprazan 20 mg+amoxicillin 750 mg+clarithromycin 200 mg twice/day) for 7 days, with stratification by age, sex, H. pylori antimicrobial resistance and institution. Eradication success was evaluated by 13C-urea breath test at least 4 weeks after treatment. Results Between October 2018 and June 2019, 629 subjects were screened and 335 were randomised. The eradication rates of VA-dual and VAC-triple therapies were 84.5% and 89.2% (p=0.203) by intention-to-treat analysis, respectively, and 87.1% and 90.2% (p=0.372) by per-protocol analysis, respectively. VA-dual was non-inferior to VAC-triple in the per-protocol analysis. The eradication rates in strains resistant to clarithromycin for VA-dual were significantly higher than those for VAC-triple (92.3% vs 76.2%; p=0.048). The incidence of adverse events was equal between groups. Conclusion The 7-day vonoprazan and low-dose amoxicillin dual therapy provided acceptable H. pylori eradication rates and a similar effect to vonoprazan-based triple therapy in regions with high clarithromycin resistance. Trial registration number UMIN000034140.Keywords
Funding Information
- Nihon University School of Medicine
This publication has 45 references indexed in Scilit:
- Antimicrobial Susceptibility‐Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin ResistanceHelicobacter, 2015
- Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2015
- Optimised empiric triple and concomitant therapy forHelicobacter pylorieradication in clinical practice: the OPTRICON studyAlimentary Pharmacology & Therapeutics, 2015
- High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori InfectionClinical Gastroenterology and Hepatology, 2014
- Randomised clinical trial comparing sequential and concomitant therapies forHelicobacter pylorieradication in routine clinical practiceGut, 2013
- Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumptionGut, 2012
- Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trialThe Lancet, 2011
- Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statisticsStatistics in Medicine, 2002
- Comparison of lansoprazole‐based triple and dual therapy for treatment of Helicobacter pylori‐related duodenal ulcer: an Asian multicentre double‐blind randomized placebo controlled studyAlimentary Pharmacology & Therapeutics, 2000
- Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutantJournal of Medical Microbiology, 1996